Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma.

Zhang, Ying; Le, Trong Kim; Shaw, James W; Kotapati, Srividya

Zhang, Ying; Le, Trong Kim; Shaw, James W; Kotapati, Srividya.

Afiliación

Zhang Y; Center for Observational Research and Data Sciences, Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb Research and Development, Hopewell, NJ, USA.
Le TK; Center for Observational Research and Data Sciences, Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb Research and Development, Hopewell, NJ, USA.
Shaw JW; Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb Research and Development, Princeton, NJ, USA.
Kotapati S; Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb Research and Development, Wallingford Center, CT, USA.

Clinicoecon Outcomes Res ; 7: 397-407, 2015.

Article en En | MEDLINE | ID: mdl-26229494

Palabras clave

adjuvant melanoma; claims data; cost analysis; interferon

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Aspecto: Implementation_research Idioma: En Revista: Clinicoecon Outcomes Res Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Nueva Zelanda

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google